drugset
drugset / Trial / NCT05065398

A Phase II Clinical Trial to Evaluate HLX208 in Advanced Non-small Cell Lung Cancer Patients With BRAF V600 Mutation

NCT05065398 ↗

Phase 2 Unknown 20 enrolled Shanghai Henlius Biotech
NaSingle-groupOpen-labelTreatment

Summary

Evaluate the efficacy，safety and pharmacokinetics of HLX208 in advanced non-small cell lung cancer patients with BRAF V600 mutation

Timeline

Start
2021-11-15
Primary completion
2023-06-30
Completion
2023-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject HLX208 Unknown 450 mg Oral

Indications

non-small cell lung carcinoma